[Effect of melatonin on activity of superoxide dismutase (CuZn-SOD) in erythrocytes of patients during short- and long-term hypokinesis]. 2010

Małgorzata Mrowicka, and Paweł Garncarek, and Elzbieta Miller, and Józef Kedziora, and Janusz Smigielski, and Katarzyna Malinowska, and Jerzy Mrowicki
Zakład Chemii i Biochemii Klinicznej Uniwersytetu Medycznego w Łodzi. malgorzata.mrowicka@umed.lodz.pl

BACKGROUND Short- or long-lasting hypokinesis is to a large degree the consequence of negative habits of human beings towards a comfortable and more sedentary lifestyle. The period of decreased physical activity can cause disturbance in the balance between systemic processes of the oxidation and reduction, which leads to an increase in reactive oxygen species (ROS) and oxidative stress generation. The aim of the study was to determine the effect of melatonin administration on the cellular superoxide dismutase (CuZn-SOD) activity in red blood cells of patients with short- and long-term hypokinesis as compared to the group of subjects with normal physical activity. METHODS The study included 33 subjects with immobilization. The study group was divided into two subgroups (depending on hypokinesis duration): group A: 15 subjects classified for total hip alloplasty (a short-lasting decrease in physical activity); group B: 18 subjects suffering from multiple sclerosis or the stroke of brain (the long-term hypokinesis). The control group (group C) comprised 17 subjects with normal physical activity. Melatonin was applied at a dose of 5 mg daily, one hour before sleep. The CuZn-SOD activity in red blood cells was determined, according to the Misra and Fridovich method, in two periods: 1) on the first day, 2) on the 10th day (group A), and 30 days (group B) after melatonin administration. RESULTS A slight increase in CuZn-SOD activity (+3.1%) was observed in group A 10 days after alloplasty and melatonin administration as compared to group B, where a considerable rise in the enzyme activity (+23.3%) was found 30 days after rehabilitation and melatonin supplementation. The average CuZn-SOD activity in both investigative groups was lower than that in the controls (group C). CONCLUSIONS It was estimated that the short- and long-lasting hypokinesis leads to an increase in ROS generation, what is confirmed by the increase in CuZn-SOD activity. The results of the study on superoxide dismutase activity indicate that oral administration of melatonin for the period of 30 days has a more favorable influence on antioxidative processes than 10-day's melatonin intake.

UI MeSH Term Description Entries
D008550 Melatonin A biogenic amine that is found in animals and plants. In mammals, melatonin is produced by the PINEAL GLAND. Its secretion increases in darkness and decreases during exposure to light. Melatonin is implicated in the regulation of SLEEP, mood, and REPRODUCTION. Melatonin is also an effective antioxidant.
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004906 Erythrocyte Count The number of RED BLOOD CELLS per unit volume in a sample of venous BLOOD. Blood Cell Count, Red,Erythrocyte Number,Red Blood Cell Count,Count, Erythrocyte,Counts, Erythrocyte,Erythrocyte Counts,Erythrocyte Numbers
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013482 Superoxide Dismutase An oxidoreductase that catalyzes the reaction between SUPEROXIDES and hydrogen to yield molecular oxygen and hydrogen peroxide. The enzyme protects the cell against dangerous levels of superoxide. Hemocuprein,Ag-Zn Superoxide Dismutase,Cobalt Superoxide Dismutase,Cu-Superoxide Dismutase,Erythrocuprein,Fe-Superoxide Dismutase,Fe-Zn Superoxide Dismutase,Iron Superoxide Dismutase,Manganese Superoxide Dismutase,Mn-SOD,Mn-Superoxide Dismutase,Ag Zn Superoxide Dismutase,Cu Superoxide Dismutase,Dismutase, Ag-Zn Superoxide,Dismutase, Cobalt Superoxide,Dismutase, Cu-Superoxide,Dismutase, Fe-Superoxide,Dismutase, Fe-Zn Superoxide,Dismutase, Iron Superoxide,Dismutase, Manganese Superoxide,Dismutase, Mn-Superoxide,Dismutase, Superoxide,Fe Superoxide Dismutase,Fe Zn Superoxide Dismutase,Mn SOD,Mn Superoxide Dismutase,Superoxide Dismutase, Ag-Zn,Superoxide Dismutase, Cobalt,Superoxide Dismutase, Fe-Zn,Superoxide Dismutase, Iron,Superoxide Dismutase, Manganese
D017382 Reactive Oxygen Species Molecules or ions formed by the incomplete one-electron reduction of oxygen. These reactive oxygen intermediates include SINGLET OXYGEN; SUPEROXIDES; PEROXIDES; HYDROXYL RADICAL; and HYPOCHLOROUS ACID. They contribute to the microbicidal activity of PHAGOCYTES, regulation of SIGNAL TRANSDUCTION and GENE EXPRESSION, and the oxidative damage to NUCLEIC ACIDS; PROTEINS; and LIPIDS. Active Oxygen Species,Oxygen Radical,Oxygen Radicals,Pro-Oxidant,Reactive Oxygen Intermediates,Active Oxygen,Oxygen Species, Reactive,Pro-Oxidants,Oxygen, Active,Pro Oxidant,Pro Oxidants,Radical, Oxygen

Related Publications

Małgorzata Mrowicka, and Paweł Garncarek, and Elzbieta Miller, and Józef Kedziora, and Janusz Smigielski, and Katarzyna Malinowska, and Jerzy Mrowicki
February 1984, Scandinavian journal of clinical and laboratory investigation,
Małgorzata Mrowicka, and Paweł Garncarek, and Elzbieta Miller, and Józef Kedziora, and Janusz Smigielski, and Katarzyna Malinowska, and Jerzy Mrowicki
January 1991, Neurologia i neurochirurgia polska,
Małgorzata Mrowicka, and Paweł Garncarek, and Elzbieta Miller, and Józef Kedziora, and Janusz Smigielski, and Katarzyna Malinowska, and Jerzy Mrowicki
June 1996, Plant & cell physiology,
Małgorzata Mrowicka, and Paweł Garncarek, and Elzbieta Miller, and Józef Kedziora, and Janusz Smigielski, and Katarzyna Malinowska, and Jerzy Mrowicki
November 1997, Journal of applied physiology (Bethesda, Md. : 1985),
Małgorzata Mrowicka, and Paweł Garncarek, and Elzbieta Miller, and Józef Kedziora, and Janusz Smigielski, and Katarzyna Malinowska, and Jerzy Mrowicki
March 1996, Journal of radiation research,
Małgorzata Mrowicka, and Paweł Garncarek, and Elzbieta Miller, and Józef Kedziora, and Janusz Smigielski, and Katarzyna Malinowska, and Jerzy Mrowicki
July 1991, Masui. The Japanese journal of anesthesiology,
Małgorzata Mrowicka, and Paweł Garncarek, and Elzbieta Miller, and Józef Kedziora, and Janusz Smigielski, and Katarzyna Malinowska, and Jerzy Mrowicki
February 1983, Acta endocrinologica,
Małgorzata Mrowicka, and Paweł Garncarek, and Elzbieta Miller, and Józef Kedziora, and Janusz Smigielski, and Katarzyna Malinowska, and Jerzy Mrowicki
May 1990, The Tokai journal of experimental and clinical medicine,
Małgorzata Mrowicka, and Paweł Garncarek, and Elzbieta Miller, and Józef Kedziora, and Janusz Smigielski, and Katarzyna Malinowska, and Jerzy Mrowicki
January 1992, Romanian journal of neurology and psychiatry = Revue roumaine de neurologie et psychiatrie,
Małgorzata Mrowicka, and Paweł Garncarek, and Elzbieta Miller, and Józef Kedziora, and Janusz Smigielski, and Katarzyna Malinowska, and Jerzy Mrowicki
January 1977, Genetika,
Copied contents to your clipboard!